Clinical Trial: Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.

Brief Summary:

Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.

The present double-blind controlled clinical pharmacology study was performed on 45 patients with cerebral infarction, who were given 75, 150, or 300 mg three times daily of sarpogrelate for 7 days in order to evaluate the dose-response relationship in terms of the precisely measured inhibition of platelet aggregation.

Detailed Summary:
Sponsor: Mitsubishi Tanabe Pharma Corporation

Current Primary Outcome: The maximum intensity of platelet aggregation on the last day of medication and as post-treatment percentage inhibition of the maximum intensity of platelet aggregation at baseline [(baseline - post-treatment )/baseline × 100 in each subject].

Original Primary Outcome: The maximam intensity of platelet aggregation on the last day of medication and as post-treatment percentage inhibition of the maximum intensity of platelet aggregation at baseline [(baseline – post-treatment )/baseline × 100 in each subject].

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mitsubishi Tanabe Pharma Corporation

Dates:
Date Received: September 4, 2005
Date Started: April 2004
Date Completion:
Last Updated: April 8, 2015
Last Verified: April 2015